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Abstract
Background: The single nucleotide polymorphism rs7566605, located in the promoter of the INSIG2 gene, has
been the subject of a strong scientific effort aimed to elucidate its possible association with body mass index (BMI).
The first report showing that rs7566605 could be associated with body fatness was a genome-wide association
study (GWAS) which used BMI as the primary phenotype. Many follow-up studies sought to validate the
association of rs7566605 with various markers of obesity, with several publications reporting inconsistent findings.
BMI is considered to be one of the measures of choice to evaluate body fatness and there is evidence that body
fatness is related with an increased risk of breast cancer (BC).
Methods: we tested in a large-scale association study (3,973 women, including 1,269 invasive BC cases and 2,194
controls), nested within the EPIC cohort, the involvement of rs7566605 as predictor of BMI and BC risk.
Results and Conclusions: In this study we were not able to find any statistically significant association between
this SNP and BMI, nor did we find any significant association between the SNP and an increased risk of breast
cancer overall and by subgroups of age, or menopausal status.
Background
Herbert and coworkers [1] conducted a genome-wide
association study (GWAS) on 694 subjects of the
Framingham Heart Study with a family-based design to
identify genetic loci (single nucleotide polymorphisms,
SNPs) contributing to obesity using body mass index
(BMI) as the primary phenotype. The authors reported
strong statistical evidence that the SNP rs7566605
located near the 5’ end of INSIG2 (Chr2:118,552,255)
was associated with increased BMI [1]. In this initial
study, association of rs7566605 with BMI was replicated
in ethnically distinct populations, including European
and African Americans. INSIG2 has been functionally
linked to lipid metabolism, due to its role in endogenous
cholesterol and fatty acid synthesis feedback inhibition
[2]. It is an endoplasmic reticulum membrane bound
protein that inhibits the proteolytic activation of Sterol
Response Element Binding Proteins (SREPs) in response
to cholesterol or insulin [2]. Thus, the biological func-
tion of the INSIG2 gene product is consistent with the
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A series of follow-up studies sought to validate the
association of INSIG2 rs7566605 with markers of obesity
in humans, with several publications reporting inconsis-
tent findings [3-13].
There is ample evidence that excessive body weight is
a risk factor for a number of diseases. In particular, the
evidence that body fatness is a cause of postmenopausal
breast cancer (BC) is convincing [14]. On the other
hand, body fatness is inversely associated with BC risk
in premenopausal women [14].
Body fatness directly affects levels of many circulating
hormones, such as insulin, insulin-like growth factors,
and oestrogens, creating an environment that favors car-
cinogenesis and hinders apoptosis (WCRF/AICR, 2007).
It also stimulates the body’s inflammatory response,
which may contribute to the initiation and progression
of several cancers (WCRF/AICR, 2007).
We tested the SNP association with the body-mass
index (BMI) and with BC risk in a large study of 3,973
women nested within the European Prospective Investi-
gation into Cancer and Nutrition (EPIC).
Methods
The EPIC cohort
A fully detailed description of the EPIC cohort has been
published elsewhere [15]. Briefly, EPIC consists of about
370,000 women and 150,000 men, aged 35-69, recruited
between 1992 and 2005 in 10 Western European coun-
tries. The vast majority (>97%) of subjects recruited in the
EPIC cohort are of European (’Caucasian’) origin. All
EPIC study subjects provided anthropometric measure-
ments (height, weight, and waist and hip circumferences)
and extensive, standardized questionnaire information
about medical history, diet, physical activity, smoking, and
other lifestyle factors. Women also answered questions
about menstrual and reproductive history, hysterectomy,
ovariectomy, and use of exogenous hormones for contra-
ception or treatment of menopausal symptoms. Based on
the questionnaire data, 32% of the subjects were pre-
menopausal at blood donation, 10% were peri-menopausal
or of unknown menopausal status, and 58% were post-
menopausal. About 260,000 women and 140,000 men pro-
vided a blood sample. Cases of cancer occurring after
recruitment into the cohort and blood donation are identi-
fied through local and national cancer registries in 7 of the
10 countries, and in France, Germany, and Greece by a
combination of contacts with national health insurances
and/or active follow-up through the study subjects or their
next of kin. Follow-up on vital status is achieved through
record linkage with mortality registries.
Selection of case and control subjects
Case subjects were selected among women who devel-
oped BC after blood collection. Control subjects (1-2
controls per case) were selected randomly by incidence
density sampling, matching the cases for centre of
recruitment, age at blood donation, duration of follow-
up, menopausal status at the time of blood donation
and use of exogenous hormones. This study did not
include women who were using hormone replacement
therapy (HRT) at the time of blood donation. For the
present study on BMI, 3,973 unique subjects were con-
sidered, of whom 1,269 invasive BC cases and 2,194
controls were included in the BC risk analysis. Subjects
who were not included in the breast cancer risk analysis
consisted of 108 cases with carcinomas in situ and 206
matched controls, and 123 cases (whose matched con-
trols had genotyping failure) and 125 controls (whose
matched cases had genotyping failure). Incidence density
matching was applied, resulting in the selection of 52
subjects as duplicate controls for conditional analyses.
Each control should have been free of cancer up to the
duration of follow-up of the index case. All participants
signed an informed written consent and the study was
approved by the ethical review boards of the Interna-
tional Agency for Research on Cancer, and of the colla-
borating institutions responsible for subject recruitment
in each of the EPIC recruitment centres.
DNA extraction and genotyping
DNA was extracted from blood samples on an Autopure
instrument (Qiagen, Hilden, Germany) with Puregene
chemistry (Qiagen, Hilden, Germany). The order of
DNAs from cases and controls was randomized on PCR
plates in order to ensure that an equal number of cases
and controls could be analyzed simultaneously. All the
genotyping was carried out using the Taqman assay
(Applied Biosystem, Foster City, California, USA).
Details on the genotype procedure are described else-
where [16]. All samples that did not give a reliable result
in the first round of genotyping were resubmitted to up
to two additional rounds of genotyping. Data points that
were still not filled after this procedure were left blank.
Repeated quality control genotypes (8% of the total)
showed a concordance of 99.7%.
Statistical analysis
The frequency distribution of genotypes was examined
for cases and controls and deviation of genotype fre-
quencies from the Hardy-Weinberg equilibrium was
assessed in the controls by chi-square test. Incidence
density matching was used to match controls to cases,
resulting in 52 controls being selected twice into 4,025
study subjects with genotypes. We used conditional
logistic regression for multivariate analyses to assess the
main effects of the genetic polymorphism on BC risk
assuming codominant model of inheritance. The more
common allele in the controls (C allele) was held as the
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reference category in calculating the odds ratios (OR).
All relative risk analysis were performed with the exclu-
sion of cases with carcinomas in situ (n = 108 cases and
206 matched controls). For this analysis incomplete
case-control sets could not be used and therefore 248
subjects were excluded. Subgroup analyses were per-
formed based on menopausal status at recruitment and
age at recruitment or diagnosis (with cutpoint at 50 or
55 years of age at diagnosis. Due to the lack of the
information on the menopausal status at diagnosis, age
at diagnosis can be used as a surrogate. In particular, we
can assume that all women older than 55 at diagnosis
were in menopause). Additional analyses were per-
formed by including cases of carcinoma in situ, and by
excluding cases diagnosed shortly (6 months, 1 or 2
years) after blood drawing.
The association between the SNP and BMI was esti-
mated by unconditional regression models, and weighted
means in each genotype category were calculated adjust-
ing for age and case-control-status. For this analysis we
could use the genotypes of all 3,973 unique subjects
subjects, regardless of case-control and matching status.
A possible association between the SNP and BMI was
investigated also with unconditional logistic regression
calculating odds ratios for genotype trend models nested
within categories of BMI as below 25 (normal weight),
25 ≤ BMI <30 (overweight) and BMI ≥ 30 (obese). This
model was compared to a main effects model with a
likelihood ratio test of 2 degrees of freedom.
Results
We explored the association between a SNP in the
INSIG2 gene promoter (rs7566605, Chr2:118,552,255)
and BMI, as well as with BC risk. We included 1,269
incident BC cases from the EPIC cohort and 2,194
matched controls for the risk and 3,973 subjects for the
BMI analysis. Table 1 summarizes the baseline charac-
teristics of cases and controls. The genotype distribution
was in Hardy-Weinberg equilibrium in controls, with a
non-significant chi square value (data not shown). The
frequencies and distribution of the genotypes and the
odds ratios for the association with BMI and BC risk are
described in Table 2.
We observed no statistically significant association
between the SNP and the geometric means of BMI. We
performed an additional analysis by categorizing subjects
with BMI ≥ 30 as obese, 25 ≤BMI <30 as overweight
and <25 as normal weight, and calculating odds ratios
for obese or overweight versus normal weight with
unconditional logistic regression, but we found no statis-
tically significant association. We performed the analysis
considering the cases and the controls separate or
together and the results obtained did not change. We
have also stratified for menopausal status at baseline
and we did not find any difference in the genotype dis-
tribution. (data not shown).
We performed also an analysis of BC risk. We found
no statistically significant associations with risk overall
and stratified by age or menopausal status, with codomi-
nant model. Additional analyses performed by including
cases of carcinoma in situ, or excluding cases diagnosed
shortly after blood drawing, showed essentially the same
results as using all cases and controls (data not shown).
Discussion
In this report we explored the possible association
between a SNP in the INSIG2 gene and BMI and with
BC risk in a large population from the EPIC cohort.
In recent years the search for genetic factors predis-
posing to obesity has intensified. Several candidate and
GWAS have been performed, and have led to the identi-
fication of a number of common common genetic
variants related to obesity [[6,17-19], Walley, 2009
#167, [20]].
The INSIG2 gene is a good candidate for being related
to obesity because of its function in lipid metabolism,
particularly in blocking the processing of SREBPs in
response to cholesterol or insulin. A SNP lying approxi-
mately 10 kb upstream from INSIG2, and thus poten-
tially affecting the transcriptional activity of the gene,
rs7566605, has been found to be associated with BMI in
a family-based GWAS [1]. Replication of this result has
been attempted in multiple studies, with some studies
confirming an association [3,4,6-13,21] and some others
not finding it [3,4,6-13,21]. Recently a meta-analysis has
been published on the association of this SNP in
INSIG2 and obesity [22] The results of the study from
Heid and collaborators suggests that the association is
potentially valid but also suggests the possibility that
heterogeneity could hinder possible findings if not taken
into account properly.
Thus, evidence for or against the association of this
SNP with obesity is still needed. We sought to provide
it, at least for the Caucasian population, with a study
nested within the EPIC cohort. EPIC is an ideal setting,
since it has a large population size, accurate phenotypic
information on BMI for all subjects, and the presence of
both pre-menopausal and post-menopausal women. We
tested the effect of rs7566605 on BMI and, at the same
time, on BC risk.
We exhaustively analyzed the possible associations
between the SNP, BMI and BC risk.. Moreover, sub-
group analyses were performed based on menopausal
status and age. We have found no statistical association
between the polymorphism and the two selected end-
points.
We had greater than 99% power to replicate the asso-
ciation of the SNP with BMI, and greater than 80%
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power to detect an association between rs7566605 and
BC risk, with an odds ratio of at least 1.3 and a type 1
error of 0.05.
A possible limitation of this report could be the fact
the majority of women and BC cases included in the
study are post-menopausal. The power among pre-
menopausal women was of 0.81 to detect an OR of 1.3
in a log additive model, hence we cannot exclude a
minor effect of the variant allele on BC risk in pre-
menopausal subjects. Moreover a possible explanation
for a lack of association of this polymorphism with the
two endpoints could be the role of gene-environment
interactions.
Conclusions
In conclusion, we have studied association of the poly-
morphism rs7566605, located near the 5’ end of the
INSIG2 gene, with BMI and BC risk within the EPIC
study and we can confidently exclude a major role of
this polymorphism with respect to both end-points in
this population.
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Mean age at diagnosis 57.5 (43.5-70.0)b -
Height 161.4 (151.0-172.0)b 160.7 (150.0-172.0)b
Weight 67.6 (51.7-89.0)b 67.3 (51.0-89.5)b
Body mass index 26.0 (20.3-34.5)b 26.1 (20.1-35.0)b
a Subjects with carcinomas in situ and their matched controls were not included in the BC risk analysis.
b Mean (5th - 95th percentiles).
*52 duplicated controls are included in this total.
Table 2 Association of rs7566605 with BMI and BC risk
rs7566605 CC GC GG P-values
Cases 562 572 135
Controls 944 1,008 242
OR a (BC risk) 1 0.95 (0.82-1.10) 0.93 (0.74-1.19) 0.466c
Normal weight (BMI <25) 797 862 208
Overweight (BMI <30) 656 624 143
Obese (BMI ≥30) 295 308 80
BMIb 26.08 (25.87-26.30) 26.00 (25.78-26.21) 26.05 (25.62-26.48) 0.697c
OR overweight or obesed 1 0.90 (0.79-1.03) 0.88 (0.71-1.08) 0.104c
OR obesed 1 0.95 (0.79-1.15) 1.00 (0.75-1.34) 0.823c
aOR: odds ratio for BC risk from conditional logistic regression analysis on matched data; cases of carcinoma in situ and their controls were excluded from the
analysis, the C allele was taken as reference.
bBody Mass Index. Adjusted for age and case-control status; cases of carcinoma in situ and their controls were included in the analysis, mean (5th - 95th
percentiles).
cP test of trend.
dOR: odds ratio from unconditional logistic regression comparing this outcome to normal weight, adjusted for age and case-control-status. The C allele was taken
as reference.
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